These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11972397)

  • 21. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.
    Wadler S; Levy D; Frederickson HL; Falkson CI; Wang Y; Weller E; Burk R; Ho G; Kadish AS;
    Gynecol Oncol; 2004 Mar; 92(3):957-64. PubMed ID: 14984966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.
    Viladiu P; Bosch FX; Castellsagué X; Muñoz N; Escribà JM; Hamsíkova E; Hofmannova V; Guerrero E; Izquierdo A; Navarro C; Moreo P; Izarzugaza I; Ascunce N; Gili M; Muñoz MT; Tafur L; Shah KV; Vonka V
    J Clin Oncol; 1997 Feb; 15(2):610-9. PubMed ID: 9053484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer.
    Brake T; Connor JP; Petereit DG; Lambert PF
    Cancer Res; 2003 Dec; 63(23):8173-80. PubMed ID: 14678972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients.
    Dang C; Koehler A; Forschner T; Sehr P; Michael K; Pawlita M; Stockfleth E; Nindl I
    Br J Dermatol; 2006 Jul; 155(1):129-36. PubMed ID: 16792764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies.
    Stacey SN; Eklund C; Jordan D; Smith NK; Stern PL; Dillner J; Arrand JR
    Oncogene; 1994 Feb; 9(2):635-45. PubMed ID: 7507231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of HPV-18 and variants of E6 gene isolated from cervical cancer patients in Taiwan.
    Chang CH; Chen TH; Hsu RC; Chou PH; Yang JJ; Hwang GY
    J Clin Virol; 2005 Jan; 32(1):33-7. PubMed ID: 15572004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer.
    Dillner L; Zellbi A; Avall-Lundqvist E; Heino P; Eklund C; Pettersson CA; Forslund O; Hansson BG; Grandien M; Bistoletti P
    Cancer Detect Prev; 1995; 19(5):381-93. PubMed ID: 7585724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later.
    Lehtinen M; Pawlita M; Zumbach K; Lie K; Hakama M; Jellum E; Koskela P; Luostarinen T; Paavonen J; Pukkala E; Sigstad E; Thoresen S; Dillner J
    Am J Obstet Gynecol; 2003 Jan; 188(1):49-55. PubMed ID: 12548195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.
    Anantharaman D; Gheit T; Waterboer T; Abedi-Ardekani B; Carreira C; McKay-Chopin S; Gaborieau V; Marron M; Lagiou P; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Talamini R; Simonato L; Castellsague X; Macfarlane TV; Biggs AM; Thakker N; Znaor A; Thomson P; Canova C; Conway DI; Healy CM; Tommasino M; Pawlita M; Brennan P
    J Natl Cancer Inst; 2013 Apr; 105(8):536-45. PubMed ID: 23503618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions.
    Andersson K; Waterboer T; Kirnbauer R; Slupetzky K; Iftner T; de Villiers EM; Forslund O; Pawlita M; Dillner J
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):189-95. PubMed ID: 18199724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus-31-related types predict better survival in cervical carcinoma.
    Huang LW; Chao SL; Hwang JL
    Cancer; 2004 Jan; 100(2):327-34. PubMed ID: 14716768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients.
    Ravaggi A; Romani C; Pasinetti B; Tassi RA; Bignotti E; Bandiera E; Odicino FE; Ragnoli M; Donzelli C; Falchetti M; Calza S; Santin AD; Pecorelli S
    Arch Virol; 2006 Oct; 151(10):1899-916. PubMed ID: 16732494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of antibodies against human papillomavirus type 16 E4 and E7 proteins in sera of patients with cervical neoplasias.
    Stoian M; Repanovici R
    Rev Roum Virol; 1994; 45(3-4):185-92. PubMed ID: 7619739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
    Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
    Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-mutation of HPV16 E6 and E7 genes in Thai squamous cervical carcinomas.
    Vaeteewoottacharn K; Jearanaikoon P; Ponglikitmongkol M
    Anticancer Res; 2003; 23(2C):1927-31. PubMed ID: 12820481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of physical status of human papillomavirus 16 in cervical cancer tissue and SiHa cell line by multiplex real-time polymerase chain reaction].
    Zheng Y; Peng ZL; Lou JY; Wang H
    Ai Zheng; 2006 Mar; 25(3):373-7. PubMed ID: 16536998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
    Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
    Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A population-based seroepidemiological study of cervical cancer.
    Dillner J; Lenner P; Lehtinen M; Eklund C; Heino P; Wiklund F; Hallmans G; Stendahl U
    Cancer Res; 1994 Jan; 54(1):134-41. PubMed ID: 8261434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.